Can routine lab results distinguish two stroke types?
A ten-biomarker model reached an AUC of 0.902 in 495 later patients at the same Chinese hospital. The result is promising decision-support research, but unknown blood-draw timing, no stroke mimics and no external hospital mean it cannot replace emergency brain imaging.
The short version
- What happened
- Development used 12,213 hospitalised stroke patients from 2013–2023: 3,251 with intracerebral haemorrhage and 8,962 with ischaemic stroke. The same hospital supplied a later 495-patient validation cohort.
- Who it affects
- Patients with suspected stroke still need emergency assessment and brain imaging; a laboratory score must not delay or replace either.
- What remains unproven
- Same-hospital temporal validation is not external multicentre validation
Keep in mind
Same-hospital temporal validation is not external multicentre validation
Unknown timing of blood draws relative to imaging and subtype-specific treatment
No stroke mimics or full emergency differential-diagnosis population
Incomplete severity, aetiology and lesion data
Retrospective missing-data assumptions and possible laboratory-platform drift
Source analysis · 1 linked source. Primary analysed source date: 15 October 2026.
Read the full report · 6 min The evidence, methods, implications and limitations
The answer: strong same-hospital discrimination, not an imaging substitute
A model combining ten routine blood and chemistry measurements distinguished intracerebral haemorrhage from acute ischaemic stroke with an AUC of 0.902 in a later group of 495 patients. Sensitivity was 89.5%, specificity 76.1%, positive predictive value 78.9% and negative predictive value 87.9%. Those results are credible enough to warrant an external prospective study, especially where rapid imaging access is difficult.
They are not safe enough to choose stroke treatment without a brain scan. Haemorrhage and arterial blockage require sharply different urgent management, and a false classification can cause severe harm. The paper explicitly says the tool is laboratory-data decision support rather than independent diagnostic confirmation. Standard emergency pathways and neuroimaging remain necessary; the model has not been tested as a replacement, nor has it shown faster treatment or better patient outcomes.[1]
What the researchers trained and tested
The retrospective development cohort contained 3,251 people with intracerebral haemorrhage and 8,962 with ischaemic stroke admitted to Xijing Hospital from 2013 through 2023. Another 2,893 people with uncomplicated hypertension were used for additional stroke-versus-control analyses. A temporal validation cohort included 153 haemorrhagic and 342 ischaemic strokes admitted to the same neurology and neurosurgery departments during 2024.
The team began with laboratory results from the first test after admission. Features with more than 30% missing data were removed, then statistical screening and three selection methods narrowed the inputs. Six supervised algorithms and eight imbalance-handling strategies were compared with ten-fold cross-validation. The selected BorderlineSMOTE-2 LightGBM model used white blood-cell count, neutrophil percentage, cystatin C, uric acid, total protein, potassium, sodium, chloride, fibrinogen degradation product and D-dimer.[1]
The later cohort is useful, but still not external validation
The 2024 cohort was kept out of model construction, including imputation, normalisation, feature engineering, resampling and hyperparameter selection. That is an important protection against direct leakage. On the non-resampled temporal cohort, the Brier score was 0.1354, the calibration slope 0.88 and the intercept 0.20. These results suggest that the model retained useful discrimination and broadly acceptable probability calibration when the calendar changed.
The hospital, departments, laboratory systems and referral population did not change. A temporal split tests drift over time, not transport to another institution. The paper's headline AUC of 0.926 refers to an internal test cohort; 0.902 is the more relevant later-cohort estimate. Neither number tells an emergency clinician how the model performs in another country, on another analyser or among patients whose symptoms ultimately prove to be migraine, seizure, tumour, low blood sugar or another stroke mimic.[1]
Blood timing is the most consequential uncertainty
The authors could not establish whether the first blood sample was collected before diagnostic imaging and treatment. Reperfusion treatment, anticoagulation reversal, intravenous fluids and the time elapsed after symptom onset can alter several laboratory measurements. If some inputs were captured after clinicians already knew the scan result or began subtype-specific care, the model may partly learn consequences of the diagnostic pathway rather than an independent pre-imaging signal.
This matters for the proposed use. A laboratory aid is most valuable when it adds information before imaging or while a scan is delayed. A prospective study must timestamp symptom onset, blood draw, imaging, treatment and model output. It should lock the assay platform and model, then test whether the score changes safe action. Retrospective accuracy calculated from uncertain workflow timing cannot establish that role.[1]
The control analyses should not be over-generalised
The model also reported AUCs above 0.9 when distinguishing either stroke subtype from a control group. Those controls were people with uncomplicated hypertension, not unselected emergency patients. The result therefore measures separation between hospitalised stroke and stable hypertension. It cannot be interpreted as general-population screening or as performance against the many acute conditions that resemble stroke.
The genetic Mendelian-randomisation analyses are exploratory and separate from the diagnostic model. They used some datasets that overlap through UK Biobank, and the genetic evidence was drawn from European-ancestry sources while the clinical model was developed in China. The authors appropriately warn against direct causal or cross-population interpretation. For practitioners, the clinically relevant result remains the same-hospital subtype classification, not proof that changing a highlighted biomarker would prevent stroke.[1]
Evidence limits and what would change the assessment
The study lacks external hospitals, prospective collection, stroke mimics, complete stroke-severity data and detailed aetiology or lesion information. Missingness was handled with K-nearest-neighbour imputation but was not formally shown to be random. Laboratory platforms and care practice may also have shifted across the long 2013–2024 period. Public Chinese research grants supported the work, and the authors declared no commercial conflict.
A decisive next study would enrol consecutive suspected-stroke patients before diagnosis at several emergency departments, timestamp blood collection, include mimics and compare the locked score with ordinary triage plus imaging. It should report treatment delay, misclassification harm, calibration by site and performance in severe, early, posterior-circulation and uncommon presentations. Until then, the model is a promising research aid that may help prioritisation where imaging is constrained; it is not a basis for thrombolysis, reversal therapy or reassurance without neuroimaging.[1]